Publications by authors named "Mitchell Garrison"

Claim this Profile
S
Social determinants of health and access to allogeneic hematopoietic cell transplantation for acute myeloid leukemia.
Natalie Wuliji, Salene M W Jones, Ted Gooley, Aaron T Gerds, Bruno C Medeiros, Mitchell Garrison

Blood· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm patients with AML.
Mohamed L Sorror, Ted A Gooley, Barry E Storer, Aaron T Gerds, Mikkael A Sekeres, Mitchell Garrison

Blood· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia.
Mohamed L Sorror, Barry E Storer, Amir T Fathi, Andrew Brunner, Aaron T Gerds, Mitchell Garrison

Blood· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer-A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib.
Lynn Symonds, Hannah Linden, Vijayakrishna Gadi, Larissa Korde, Eve Rodler, Mitchell Garrison

Clin Breast Cancer· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium.
Ajay K Gopal, Oliver W Press, Andrei R Shustov, Stephen H Petersdorf, Ted A Gooley, Mitchell A Garrison

Leuk Lymphoma· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study.
Jordi Rodon, Mitchell Garrison, Lisa A Hammond, Johann de Bono, Lon Smith

Cancer Chemother Pharmacol· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumors.
Alain C Mita, Lisa A Hammond, Peter L Bonate, Geoffrey Weiss, Heather McCreery, Mitchell Garrison

Clin Cancer Res· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid malignancies.
Garry H Schwartz, Christopher B Jones, Mitchell Garrison, Amita Patnaik, Chris Takimoto

Invest New Drugs· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies.
Mitchell A Garrison, Lisa A Hammond, Charles E Geyer, Garry Schwartz, Anthony W Tolcher

Clin Cancer Res· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenging cases and diagnostic dilemmas: case 1. Tracheal compression in Hodgkin's disease.
Mitchell A Garrison, Christopher Glanton, Mark Rasnke, Michael E Smith, Deborah L Ornstein

J Clin Oncol· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis